IGF1 and Hypsarrhythmia: Preclinical animal studies demonstrate the therapeutic potential of an IGF-1-derived tripeptide treatment, which shows significant anticonvulsant effects and suppresses hypsarrhythmia on EEG (Ballester-Rosado et al., 2025).